Chipscreen(SH:688321)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥106,525,525.73, representing a year-on-year increase of 1.96%[5] - The net profit attributable to shareholders was -¥32,476,835.40, with a net profit excluding non-recurring gains and losses at -¥38,248,035.55, both figures indicating a significant loss[5] - Total revenue for Q1 2023 was CNY 106,525,525.73, an increase from CNY 104,479,337.72 in Q1 2022, representing a growth of approximately 1.96%[19] - The net loss for Q1 2023 was CNY 35,783,904.58, compared to a net loss of CNY 3,731,829.11 in Q1 2022, reflecting a significant decline in profitability[20] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.0798, compared to CNY -0.0092 in Q1 2022, indicating a worsening in earnings performance[21] Research and Development - The total R&D investment amounted to ¥85,986,806.51, which is an increase of 32.28% compared to the previous period, accounting for 80.72% of operating revenue, up by 18.50 percentage points[6] - Research and development expenses rose to CNY 52,986,316.31 in Q1 2023, compared to CNY 36,500,212.56 in Q1 2022, marking an increase of approximately 45.4%[20] - The company is focused on enhancing its research and development capabilities to drive future growth and innovation[14] - The company continues to invest heavily in R&D, which may indicate a focus on future product development and market expansion despite current financial challenges[20] Cash Flow and Assets - The cash flow from operating activities showed a net outflow of -¥48,582,917.14, reflecting a decrease of 512.03% due to increased R&D expenditures and tax payments[6] - In Q1 2023, the net cash flow from operating activities was -48,582,917.14, a significant decline compared to 11,791,112.97 in Q1 2022[24] - Total assets at the end of the reporting period were ¥3,009,324,516.46, a 3.92% increase from the end of the previous year[6] - The total assets increased to CNY 3,009,324,516.46 in Q1 2023, up from CNY 2,895,799,412.95 in Q1 2022, showing a growth of about 3.9%[17] - The total current assets of RMB 1,253,859,413.43 as of March 31, 2023, an increase from RMB 1,184,135,081.82 as of December 31, 2022, reflecting a growth of approximately 5.7%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,866[11] - The company's equity attributable to shareholders decreased by 4.03% to ¥1,454,331,002.16 compared to the end of the previous year[6] - The company has a significant shareholder structure, with the top shareholder, 博奥生物集团有限公司, holding 34,705,162 shares, which is 8.44% of the total shares[12] - The second-largest shareholder, 深圳市海粤门生物科技开发有限公司, holds 22,936,008 shares, accounting for 5.58%[12] - The company has a total of 10 major shareholders, with the cumulative shareholding of the top 10 reaching approximately 56.5%[12] Operating Costs and Liabilities - Total operating costs for Q1 2023 were CNY 144,662,416.93, up from CNY 111,098,530.22 in Q1 2022, indicating an increase of about 30.2%[19] - Total liabilities reached CNY 1,433,830,911.03 in Q1 2023, compared to CNY 1,320,098,552.55 in Q1 2022, indicating an increase of approximately 8.6%[17] Market and Product Development - The sales volume of Seglitazone increased by 218% year-on-year after the implementation of the medical insurance price on March 1, 2023, although revenue decreased due to significant price cuts[6] - The company is actively involved in market expansion and new product development, although specific details were not disclosed in the report[14]